Expertise in
10
conditions

Dr. Deepa S. Subramaniam

Internal Medicine
MedStar Health Georgetown University
3800 Reservoir Rd NW Ste E501, 
Washington, DC 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
MedStar Health Georgetown University
3800 Reservoir Rd NW Ste E501, 
Washington, DC 

Overview

Deepa Subramaniam is a primary care provider, practicing in Internal Medicine in Washington, Washington, D.c..

Dr. Subramaniam is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

She is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 17 clinical trials.

Specialties

Internal Medicine

Licenses

Specialist in DC

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

MedStar Health Georgetown University
3800 Reservoir Rd NW Ste E501, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Enrollment Status: Recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 18, 2026
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Enrollment Status: Completed
Publish Date: July 31, 2024
Intervention Type: Drug
Study Drugs: Ramucirumab, Pembrolizumab
Study Phase: Phase 1
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Enrollment Status: Terminated
Publish Date: July 05, 2024
Intervention Type: Drug
Study Drugs: Dasatinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug
Study Drug: INC280
Study Phase: Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
Enrollment Status: Terminated
Publish Date: February 16, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
View 9 Less Clinical Trials

44 Total Publications

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 18, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Thomas B. Nutman
Internal Medicine
Expertise in
19
conditions
Dr. Thomas B. Nutman
Internal Medicine

Office

4 Center Dr Bldg 4 Rm B1-03, 
Bethesda, MD 
 (4.7 miles away)
301-496-5398
Languages Spoken:
English
See accepted insurances

Thomas Nutman is a primary care provider, practicing in Internal Medicine in Bethesda, Maryland. Dr. Nutman is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Secernentea Infections, Helminthiasis, Spirurida Infections, and Childhood Volvulus.

Expertise in
33
conditions
Dr. Ron Waksman
Internal Medicine
Expertise in
33
conditions
Dr. Ron Waksman
Internal Medicine
Before you request

110 Irving Street Northwest Suite 4B-1

110 Irving St NW Ste 4B-1, 
Washington, DC 
 (2.9 miles away)
202-877-7464
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ron Waksman is a primary care provider, practicing in Internal Medicine in Washington, Washington, D.c.. Dr. Waksman is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Coronary Heart Disease, Heart Attack, Acute Coronary Syndrome, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement. Dr. Waksman is currently accepting new patients.

Expertise in
19
conditions
Dr. Iago Pinal-Fernandez
Internal Medicine
Expertise in
19
conditions
Dr. Iago Pinal-Fernandez
Internal Medicine

Nih Niams Building 50

Bethesda, MD 
 (4.7 miles away)
202-361-2183
Languages Spoken:
English

Iago Pinal-Fernandez is a primary care provider, practicing in Internal Medicine in Bethesda, Maryland. Dr. Pinal-Fernandez is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Myositis, Polymyositis, Dermatomyositis, Antisynthetase Syndrome, and Lung Transplant.

Frequently Asked Questions about Dr. Deepa S. Subramaniam

How do I make an appointment with Dr. Deepa S. Subramaniam?

You can book an appointment with Dr. Deepa S. Subramaniam by calling their office at 202-444-2198. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Deepa S. Subramaniam a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Deepa S. Subramaniam is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Deepa S. Subramaniam specialize in?

While Dr. Deepa S. Subramaniam is a Internal Medicine, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Deepa S. Subramaniam participate in research or clinical trials?

Yes. Dr. Deepa S. Subramaniam has published 44 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Deepa S. Subramaniam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Deepa S. Subramaniam accept my insurance?

Dr. Deepa S. Subramaniam accepts most major insurance plans, including Medicare. We recommend calling the office directly at 202-444-2198 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Subramaniam's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile